Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7772243 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
Aug, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(1 year, 1 month from now) | |
US10603314 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(1 year, 10 months from now) | |
US10596162 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(1 year, 10 months from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Sep 27, 2025 |
Market Authorisation Date: 27 September, 2018
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a u...
Dosage: TABLET;ORAL